       Document 0001
 DOCN  M9640001
 TI    Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the
       rheumatoid joint is associated with clinical improvement. Implications
       for the development of immunotherapeutic dosing regimens.
 DT    9604
 AU    Choy EH; Pitzalis C; Cauli A; Bijl JA; Schantz A; Woody J; Kingsley GH;
       Panayi GS; Guy's Hospital, UMDS, London, England.
 SO    Arthritis Rheum. 1996 Jan;39(1):52-6. Unique Identifier : AIDSLINE
       MED/96133261
 AB    OBJECTIVE. We assessed the effect of a daily dosing schedule of the
       chimeric anti-CD4 monoclonal antibody (MAb), cM-T412, in rheumatoid
       arthritis (RA) patients, and compared lymphocyte changes in the
       peripheral blood (PB) and synovial fluid (SF) of these patients.
       METHODS. Twelve patients received 50 mg/day of cM-T412 for 5 days,
       followed by a maintenance treatment of 50 mg/week for 5 weeks (6
       patients), or a retreatment course of 50 mg/day for 5 days after 5 weeks
       (6 patients). Paired PB and SF samples were obtained during treatment
       for analysis. RESULTS. Changes in lymphocyte count and coating with the
       MAb in PB did not reflect changes in the SF. After 5 daily treatments,
       the percentage of cM-T412-coated CD4+ lymphocytes in SF correlated with
       the degree of clinical improvement seen in patients at 2 weeks after the
       initiation of therapy (r = 0.75, P < 0.05). CONCLUSION. These results
       demonstrate the importance of antibody dosage and treatment regimen in
       determining clinical benefit. Our findings suggest that the percentage
       of cM-T412-coated CD4+ lymphocytes in SF may be a predictor of clinical
       outcome.
 DE    Adult  Aged  Antibodies, Monoclonal/*THERAPEUTIC USE  Antigens,
       CD4/*IMMUNOLOGY  Arthritis, Rheumatoid/*BLOOD/COMPLICATIONS/*THERAPY
       Comparative Study  CD4 Lymphocyte Count  *CD4-Positive T-Lymphocytes
       Drug Administration Schedule  Human  Middle Age  Support, Non-U.S. Gov't
       Synovial Fluid/*CYTOLOGY  Time Factors  Treatment Outcome  CLINICAL
       TRIAL  JOURNAL ARTICLE  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

